Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity and epitope demonstrated in several preclinical assays First subject dosed with ORKA-002 expected in Q3 2025 MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biolog ...